Fennec Pharmaceuticals (FENC) Non-Current Deffered Revenue (2023 - 2025)
Fennec Pharmaceuticals (FENC) posted Non-Current Deffered Revenue of $24.6 million for Q4 2025, little changed on a QoQ basis from $24.6 million in Q3 2025, and little changed year-over-year from $24.6 million in Q4 2024.
Fennec Pharmaceuticals (FENC) Non-Current Deffered Revenue (2023 - 2025) Analysis & Trends
Fennec Pharmaceuticals' Non-Current Deffered Revenue history runs 3 years deep, the most recent figure standing at $24.6 million for Q4 2025.
- Quarterly Non-Current Deffered Revenue changed 0.0% year-over-year to $24.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $24.6 million (changed 0.0% YoY) and the FY2025 annual result came in at $24.6 million, changed 0.0% from the prior year.
- Non-Current Deffered Revenue was $24.6 million for Q4 2025 at Fennec Pharmaceuticals, roughly flat from $24.6 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $25.0 million in Q1 2024 and bottomed at $2000.0 in Q4 2023.
- A 3-year average of $21.9 million and a median of $24.6 million in 2024 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2024 — Non-Current Deffered Revenue surged 1227950.0% — and 2025, when it slipped 1.73%.
- Fennec Pharmaceuticals' Non-Current Deffered Revenue stood at $2000.0 in 2023, then jumped by 1227950.0% to $24.6 million in 2024, then changed by 0.0% to $24.6 million in 2025.
- Business Quant data shows FENC's Non-Current Deffered Revenue at $24.6 million in Q4 2025, $24.6 million in Q3 2025, and $24.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Fennec Pharmaceuticals | 346.75 Mn | 309.97 Mn | 12.01 Mn | 24.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 24.56 Mn |
| Sep 30, 2025 | 24.56 Mn |
| Jun 30, 2025 | 24.56 Mn |
| Mar 31, 2025 | 24.56 Mn |
| Dec 31, 2024 | 24.56 Mn |
| Sep 30, 2024 | 24.56 Mn |
| Jun 30, 2024 | 24.99 Mn |
| Mar 31, 2024 | 24.99 Mn |
| Dec 31, 2023 | 2,000.00 |